With multiple offices throughout the US, a new business unit within a large corporation is focused on improving the quality, affordability and equity of employer-sponsored health care. This new investment arm is investing from the corporate’s balance sheet in early-stage and advanced health companies that offer accountable care and value-based solutions to employers and employees.
The firm’s “sweet spot” is in Series B and beyond. While the organization primarily deploys growth equity capital, it can consider making investments into earlier stage companies. The firm can invest in, and will consider opportunities outside of the U.S. market, but these opportunities must be focused on the employer-sponsored insurance market in the U.S.
Within healthcare, the firm invests primarily in accountable care-centered solutions and integrated disease management programs. The firm’s core focus areas are care delivery, priority conditions, analytics & enablers of advanced medical care, and pharma services.
The firm is also focused on health solutions that can be implemented in a remote or at-home setting, reducing the burden of patients. In terms of stage of development, the firm expects to see customer traction and revenue generation taking place – companies who are still developing a working product that has yet to be implemented will generally be considered too early for investment.
The firm seeks to invest in companies that have established substantial validation on their product/technology. The firm has board representation with each of the companies it has invested in and has typically served as a syndicate partner to lead investors.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply